Inversago is a privately-owned company. In 2018, Inversago has secured a $7 million series A financing to pursue its development plan and advance its CB1 platform as a potent treatment for targeted diseases.

The company’s first financing round was co-led by Genesys Capital and Amorchem, with participation from the JDRF T1D Fund, Accel-Rx, Anges Québec Capital, Anges Québec, Tarnagulla Ventures and angel investors.


Inversago also acknowledges the continued financial support the company received from the Foundation for Prader-Willi Research (FPWR), with two consecutive annual grants supporting research and development activities of INV-101.


For more information on investment opportunities, please contact us: